John V Heymach Selected Research

Angiogenesis Inhibitors

10/2019	Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
1/2017	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer.
12/2015	Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
11/2012	Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
4/2011	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
3/2010	Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
9/2006	Angiogenesis inhibitors for lung cancer: clinical developments and future directions.
3/2006	Emerging antiangiogenic agents in lung cancer.
12/2005	Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
5/2005	Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John V Heymach Research Topics

Disease

176	Neoplasms (Cancer) 11/2022 - 09/2004
126	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 03/2006
67	Lung Neoplasms (Lung Cancer) 08/2022 - 06/2004
25	Neoplasm Metastasis (Metastasis) 05/2022 - 09/2012
21	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 06/2004
20	Adenocarcinoma of Lung 05/2022 - 10/2006
11	Hypoxia (Hypoxemia) 01/2021 - 02/2007
11	Disease Progression 01/2021 - 05/2009
11	Squamous Cell Carcinoma of Head and Neck 01/2021 - 06/2010
9	Carcinogenesis 01/2021 - 01/2012
7	Adenocarcinoma 03/2021 - 07/2015
6	Melanoma (Melanoma, Malignant) 01/2022 - 04/2010
6	Breast Neoplasms (Breast Cancer) 12/2018 - 12/2008
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 10/2017
5	Brain Neoplasms (Brain Tumor) 01/2021 - 06/2008
5	Exanthema (Rash) 01/2020 - 07/2010
4	Malignant Mesothelioma 10/2020 - 06/2008
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 04/2011
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2015 - 05/2009
3	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 07/2011
3	COVID-19 11/2021 - 01/2021
3	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 09/2004
3	Carcinoma (Carcinomatosis) 01/2020 - 10/2006
3	Ovarian Neoplasms (Ovarian Cancer) 04/2017 - 01/2007
3	Leukemia 01/2017 - 05/2012
3	Colorectal Neoplasms (Colorectal Cancer) 01/2013 - 01/2010
2	Sepsis (Septicemia) 01/2022 - 02/2018
2	Lymphoma (Lymphomas) 01/2022 - 01/2021

Drug/Important Bio-Agent (IBA)

32	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2007
28	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2008
23	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 05/2005
21	ErbB Receptors (EGF Receptor)IBA 12/2021 - 07/2006
18	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2016
16	Pharmaceutical PreparationsIBA 01/2021 - 01/2005
15	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 07/2006
15	vandetanib (ZD6474)IBA 04/2016 - 07/2006
13	Tyrosine Kinase InhibitorsIBA 01/2021 - 05/2007
12	CytokinesIBA 01/2022 - 01/2010
12	Phosphotransferases (Kinase)IBA 01/2021 - 12/2007
11	LigandsIBA 01/2021 - 09/2012
11	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 02/2016
11	Angiogenesis InhibitorsIBA 10/2019 - 09/2004
10	Bevacizumab (Avastin)FDA Link 01/2021 - 03/2006
9	Biological ProductsIBA 01/2020 - 01/2005
9	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 01/2012
9	Docetaxel (Taxotere)FDA Link 01/2020 - 01/2007
8	PlatinumIBA 01/2022 - 08/2011
8	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 02/2007
8	RNA (Ribonucleic Acid)IBA 10/2021 - 02/2016
8	Circulating Tumor DNAIBA 01/2021 - 03/2016
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2012 - 09/2004
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2022 - 10/2017
7	Gefitinib (Iressa)FDA Link 05/2009 - 07/2006
6	Messenger RNA (mRNA)IBA 01/2020 - 05/2008
6	Paclitaxel (Taxol)FDA LinkGeneric 12/2013 - 11/2008
5	HM781-36BIBA 11/2022 - 10/2019
5	AntigensIBA 01/2022 - 05/2014
5	Peptides (Polypeptides)IBA 01/2022 - 03/2014
5	B7-H1 AntigenIBA 01/2021 - 02/2016
5	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2007
5	Carboplatin (JM8)FDA LinkGeneric 12/2013 - 11/2008
4	AntibodiesIBA 01/2022 - 04/2011
4	NucleotidesIBA 01/2022 - 08/2013
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018 - 11/2013
4	Sorafenib (BAY 43-9006)FDA Link 10/2016 - 06/2011
4	Cetuximab (Erbitux)FDA Link 12/2013 - 07/2006
3	NivolumabIBA 11/2022 - 01/2018
3	IpilimumabIBA 11/2022 - 12/2019
3	osimertinibIBA 01/2022 - 12/2018
3	InterleukinsIBA 01/2022 - 03/2010
3	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 09/2012
3	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 05/2012
3	Transcription Factors (Transcription Factor)IBA 01/2021 - 08/2009
3	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2021 - 03/2010
3	pembrolizumabIBA 10/2020 - 01/2020
3	Small Interfering RNA (siRNA)IBA 01/2020 - 04/2017
3	ChemokinesIBA 01/2020 - 07/2011
3	Protons (Proton)IBA 01/2020 - 01/2017
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 08/2013
3	cediranib (AZD2171)IBA 10/2019 - 08/2007
3	MicroRNAs (MicroRNA)IBA 01/2019 - 08/2014
3	EnzymesIBA 01/2019 - 01/2010
3	pazopanib FDA Link 01/2018 - 03/2010
3	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2017 - 09/2008
3	Sunitinib (Sutent)FDA Link 11/2012 - 05/2007
3	afliberceptIBA 11/2011 - 12/2008
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2011 - 01/2005
2	trametinibIBA 01/2022 - 01/2020
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 01/2015
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 01/2017
2	durvalumabIBA 01/2022 - 01/2022
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2021 - 06/2010

Therapy/Procedure

85	Therapeutics 08/2022 - 01/2005
37	Drug Therapy (Chemotherapy) 11/2022 - 06/2004
37	Radiotherapy 01/2022 - 04/2011
22	Immunotherapy 08/2022 - 01/2016
6	Neoadjuvant Therapy 01/2022 - 01/2018
4	Aftercare (After-Treatment) 01/2021 - 09/2016
3	Chemoradiotherapy 01/2022 - 01/2013
3	Proton Therapy 01/2021 - 01/2018